Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Blockade of STAT3/IL-4 overcomes EGFR T790M-cis-L792F-induced resistance to osimertinib via suppressing M2 macrophages polarization
Yiting Sun, Yiting Dong, Xijuan Liu, et al.
EBioMedicine (2022) Vol. 83, pp. 104200-104200
Open Access | Times Cited: 17

Showing 17 citing articles:

Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance
Shujing Wang, Jingrui Wang, Zhiqiang Chen, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 98
Tumor-associated macrophages affect the treatment of lung cancer
Zhuchen Yu, Juntao Zou, Fei Xu
Heliyon (2024) Vol. 10, Iss. 7, pp. e29332-e29332
Open Access | Times Cited: 4
HUNK as a key regulator of tumor-associated macrophages in triple negative breast cancer
Nicole Ramos Solis, Anthony Cannon, Tinslee Dilday, et al.
OncoImmunology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 4
Roles of IL-4, IL-13, and Their Receptors in Lung Cancer
Yao Zhang, Kangle Zhu, Xiao Wang, et al.
Journal of Interferon & Cytokine Research (2024) Vol. 44, Iss. 9, pp. 399-407
Closed Access | Times Cited: 3
TIAM2 Contributes to Osimertinib Resistance, Cell Motility, and Tumor-Associated Macrophage M2-like Polarization in Lung Adenocarcinoma
Liang Lu, Hua He, Shiyao Jiang, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 18, pp. 10415-10415
Open Access | Times Cited: 15
Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects
Daoan Cheng, Kele Ge, Xue Yao, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 8
Overcoming EGFR-TKI resistance by targeting the tumor microenvironment
Jinsong Zhang, Natalie I. Vokes, Man Li, et al.
Chinese Medical Journal - Pulmonary and Critical Care Medicine (2024) Vol. 2, Iss. 3, pp. 151-161
Open Access | Times Cited: 2
RSK4 promotes the macrophage recruitment and M2 polarization in esophageal squamous cell carcinoma
Shuai He, Ming Lu, Liang Zhang, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2023) Vol. 1870, Iss. 3, pp. 166996-166996
Closed Access | Times Cited: 6
Novel insights into immune cells modulation of tumor resistance
Yiqing Zhou, Chuhan Na, Zhigang Li
Critical Reviews in Oncology/Hematology (2024) Vol. 202, pp. 104457-104457
Closed Access | Times Cited: 1
Bufalin inhibits the proliferation of lung cancer cells by suppressing Hippo-YAP pathway
Zijun Qian, Xiaoting Tian, Yayou Miao, et al.
Cellular Signalling (2023) Vol. 109, pp. 110746-110746
Closed Access | Times Cited: 4
IL-35: New Target for Immunotherapy Targeting the Tumor Microenvironment
Pengcheng Yi, Wenjun Yu, Yanhong Xiong, et al.
Molecular Cancer Therapeutics (2023) Vol. 23, Iss. 2, pp. 148-158
Closed Access | Times Cited: 4
circPTPN12 promotes the progression and sunitinib resistance of renal cancer via hnRNPM/IL-6/STAT3 pathway
Yi Shou, Changjie Yue, Qi Wang, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 3
Open Access | Times Cited: 3
Macrophage: Hidden Criminal in Therapy Resistance
Yi-min Ding, Qian Cao, Wenjuan Yang, et al.
Journal of Innate Immunity (2024) Vol. 16, Iss. 1, pp. 188-202
Open Access
Receptor-Based Strategies for Overcoming Resistance in Cancer Therapy
Naresh Sah, Abdul Althaf Shaik, Ganesh Acharya, et al.
Receptors (2024) Vol. 3, Iss. 4, pp. 425-443
Open Access
A strategy to overcome EGFR p.T790M cis p.L792F induced resistance to osimertinib
Umberto Malapelle, Francesco Passiglia
EBioMedicine (2022) Vol. 83, pp. 104213-104213
Open Access | Times Cited: 1
Gefitinib/osimertinib/paclitaxel

Reactions Weekly (2023) Vol. 1942, Iss. 1, pp. 136-136
Closed Access
The CCL2-CCR2 axis contributes to acquired osimertinib resistance in lung cancer by upregulating Zeb1 expression
Tzu‐Hua Chang, Meng‐Feng Tsai, Shang‐Gin Wu, et al.
Research Square (Research Square) (2023)
Open Access
Page 1

Scroll to top